{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:33:32Z","timestamp":1789187612130,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2021YFQ0029"],"award-info":[{"award-number":["2021YFQ0029"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clon.2025.103776","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T21:47:06Z","timestamp":1738273626000},"page":"103776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparing the Effectiveness and Safety of First-line Interventions in Patients With Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer, With Particular Focus on Brain Metastatic Status: A Systematic Review and Network Meta-analysis"],"prefix":"10.1016","volume":"40","author":[{"given":"T.","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clon.2025.103776_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.clon.2025.103776_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-small-cell lung cancers: a heterogeneous set of diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.clon.2025.103776_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A\u00a0prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non\u2013small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10","key":"10.1016\/j.clon.2025.103776_bib4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.clon.2025.103776_bib5","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.clon.2025.103776_bib6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.clon.2025.103776_bib7","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon\u2013small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.clon.2025.103776_bib8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.clon.2025.103776_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI\u2013targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Cancer"},{"issue":"21","key":"10.1016\/j.clon.2025.103776_bib10","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.clon.2025.103776_bib11","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.clon.2025.103776_bib12","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.clon.2025.103776_bib13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S2213-2600(23)00183-2","article-title":"Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.clon.2025.103776_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11523-022-00941-7","article-title":"Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies","volume":"18","author":"Popat","year":"2023","journal-title":"Target Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103776_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12931-021-01741-9","article-title":"Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation","volume":"22","author":"Li","year":"2021","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.clon.2025.103776_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.clon.2025.103776_bib17","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.clon.2025.103776_bib18","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jtho.2022.07.1143","article-title":"Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study","volume":"17","author":"Shi","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103776_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.09.002","article-title":"First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial","volume":"6","author":"Zhou","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.clon.2025.103776_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.clon.2025.103776_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"7109","key":"10.1016\/j.clon.2025.103776_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.clon.2025.103776_bib23","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.clon.2025.103776_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.clon.2025.103776_bib25","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clon.2025.103776_bib26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1200\/JCO.19.01154","article-title":"Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer","volume":"38","author":"Noronha","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.clon.2025.103776_bib27","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ijc.30806","article-title":"Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial","volume":"141","author":"Han","year":"2017","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.clon.2025.103776_bib28","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clon.2025.103776_bib29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clon.2025.103776_bib30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.clon.2025.103776_bib31","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1200\/JCO.22.02547","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"41","author":"Sequist","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2025.103776_bib32","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.clon.2025.103776_bib33","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clon.2025.103776_bib34","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clon.2025.103776_bib35","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jtho.2021.05.006","article-title":"Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)","volume":"16","author":"Zhao","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9","key":"10.1016\/j.clon.2025.103776_bib36","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jtho.2022.05.006","article-title":"Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9","key":"10.1016\/j.clon.2025.103776_bib37","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2022.05.008","article-title":"Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial","volume":"17","author":"Piccirillo","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2025.103776_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107349","article-title":"A\u00a0randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-na\u00efve patients with non-small cell lung cancer harboring EGFR mutations","volume":"184","author":"Ninomiya","year":"2023","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.clon.2025.103776_bib39","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.clon.2025.103776_bib40","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1200\/JCO.2016.66.9218","article-title":"Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations","volume":"34","author":"Cheng","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.clon.2025.103776_bib41","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clon.2025.103776_bib42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clon.2025.103776_bib43","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103776_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mds214","article-title":"Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-na\u00efve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clon.2025.103776_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clon.2025.103776_bib46","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clon.2025.103776_bib47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2019.05.008","article-title":"Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study","volume":"133","author":"Xu","year":"2019","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.clon.2025.103776_bib48","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jamaoncol.2019.1847","article-title":"Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial","volume":"5","author":"Stinchcombe","year":"2019","journal-title":"JAMA Oncol"},{"issue":"34","key":"10.1016\/j.clon.2025.103776_bib49","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.20.01149","article-title":"Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403","volume":"38","author":"Goldberg","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2025.103776_bib50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cllc.2016.07.007","article-title":"Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations","volume":"18","author":"Leighl","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clon.2025.103776_bib51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2020.09.018","article-title":"Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)","volume":"150","author":"Garcia-Campelo","year":"2020","journal-title":"Lung Cancer"},{"issue":"15","key":"10.1016\/j.clon.2025.103776_bib52","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1158\/1078-0432.CCR-20-4604","article-title":"First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study","volume":"27","author":"Cortot","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.clon.2025.103776_bib53","first-page":"2551","article-title":"Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis","volume":"136","author":"Zhu","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.clon.2025.103776_bib54","doi-asserted-by":"crossref","first-page":"l5460","DOI":"10.1136\/bmj.l5460","article-title":"Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis","volume":"367","author":"Zhao","year":"2019","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.clon.2025.103776_bib55","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/JTO.0000000000000648","article-title":"Pattern of failure analysis in metastatic EGFR-mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy","volume":"10","author":"Al-Halabi","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.clon.2025.103776_bib56","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.2147\/OTT.S300267","article-title":"Primary tumor radiotherapy during EGFR-TKI disease control improves survival of treatment na\u00efve advanced EGFR-mutant lung adenocarcinoma patients","volume":"14","author":"Hsu","year":"2021","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clon.2025.103776_bib57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2020.12.037","article-title":"Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment","volume":"153","author":"Ohtaki","year":"2021","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.clon.2025.103776_bib58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000509664","article-title":"Primary tumor resection is associated with a better outcome among advanced EGFR-mutant lung adenocarcinoma patients receiving EGFR-TKI treatment","volume":"99","author":"Tseng","year":"2021","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.clon.2025.103776_bib59","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.ctrv.2014.03.005","article-title":"Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases","volume":"40","author":"Zimmermann","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.clon.2025.103776_bib60","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-14-2082","article-title":"Bevacizumab in Patients with Nonsquamous Non\u2013Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study","volume":"21","author":"Besse","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clon.2025.103776_bib61","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1038\/s41598-022-08449-w","article-title":"The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis","volume":"12","author":"Chiu","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.clon.2025.103776_bib62","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1158\/1078-0432.CCR-08-2407","article-title":"Erlotinib and Bevacizumab Have Synergistic Activity against Melanoma","volume":"15","author":"Schicher","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.clon.2025.103776_bib63","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","article-title":"Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance","volume":"15","author":"Naumov","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2025.103776_bib64","article-title":"Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI","volume":"15","author":"Ding","year":"2024","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.clon.2025.103776_bib65","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/bjc.2016.456","article-title":"A\u00a0phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations","volume":"116","author":"Yang","year":"2017","journal-title":"Br J Cancer"},{"issue":"27","key":"10.1016\/j.clon.2025.103776_bib66","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","article-title":"Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L","volume":"34","author":"Urata","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525000317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525000317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T14:58:59Z","timestamp":1744297139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655525000317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":66,"alternative-id":["S0936655525000317"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2025.103776","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing the Effectiveness and Safety of First-line Interventions in Patients With Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer, With Particular Focus on Brain Metastatic Status: A Systematic Review and Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2025.103776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"103776"}}